ETAP-Lab
ETAP-Lab is an independent Contract Research Organization (CRO) specializing in preclinical research and pharmacology services for the pharmaceutical and agro-food industries. With over 30 years of expertise, ETAP-Lab offers high-quality, customizable models and integrated platforms to support drug development across various therapeutic areas, including neurology, neurovascular, cardiology, and dermatology. The company emphasizes scientific rigor, reproducibility, and innovative approaches such as chronobiology and natural behaviors in its models.
Industries
Nr. of Employees
small (1-50)
ETAP-Lab
13, rue du Bois de la Champelle, 54500 Vandoeuvre-lès-Nancy, FRANCE
Products
Integrated translational research platforms
A suite of integrated preclinical platforms combining in vitro models, in vivo imaging, behavioral assessments and biological analyses to generate translational data.
Integrated translational research platforms
A suite of integrated preclinical platforms combining in vitro models, in vivo imaging, behavioral assessments and biological analyses to generate translational data.
Services
Execution of therapeutic-area specific animal studies (neurology, neurovascular, cardiovascular, dermatology, GI), including surgical models, longitudinal dosing and endpoint collection.
Custom and standard in vitro pharmacology assays, receptor screening and haemostasis testing to support target validation and early pharmacology.
Design and analytical/experimental validation of sponsor-specific preclinical models and endpoints.
Behavioral study design and execution incorporating chronobiology and natural behavior measures to improve translational relevance.
Imaging-based endpoints and biological analyses including tissue histology, cytokine measurement and metabolomic profiling to support mechanistic studies.
Safety and toxicology study support for early-stage projects, including non‑GLP dermal toxicology and other preclinical safety endpoints.
Execution of therapeutic-area specific animal studies (neurology, neurovascular, cardiovascular, dermatology, GI), including surgical models, longitudinal dosing and endpoint collection.
Custom and standard in vitro pharmacology assays, receptor screening and haemostasis testing to support target validation and early pharmacology.
Design and analytical/experimental validation of sponsor-specific preclinical models and endpoints.
Behavioral study design and execution incorporating chronobiology and natural behavior measures to improve translational relevance.
Imaging-based endpoints and biological analyses including tissue histology, cytokine measurement and metabolomic profiling to support mechanistic studies.
Safety and toxicology study support for early-stage projects, including non‑GLP dermal toxicology and other preclinical safety endpoints.
Expertise Areas
- Preclinical pharmacology
- Disease model development (in vivo and in vitro)
- Behavioral neuroscience and ethology
- Neurovascular and stroke modeling
Key Technologies
- In vivo imaging
- Behavioral monitoring and ethological assessment
- Metabolomics
- HPLC
News & Updates
ETAP-Lab will present a research poster at the AFSSI Connexions 2025 in Toulouse.
ETAP-Lab will present a poster at the SPIN 2025 Congress in Paris.
ETAP-Lab will participate in the BIO 2025 convention in Boston.
Research on the tissue-repair properties of d-Limonene and Perillyl Alcohol in mouse models.
Study on the anti-stress and anti-inflammatory effects of d-Limonene and Perillyl Alcohol.
ETAP-Lab participated in the HIE & NI 2014 event in Amsterdam, showcasing its research and innovations.
ETAP-Lab will present a research poster at the AFSSI Connexions 2025 in Toulouse.
ETAP-Lab will present a poster at the SPIN 2025 Congress in Paris.
ETAP-Lab will participate in the BIO 2025 convention in Boston.
Research on the tissue-repair properties of d-Limonene and Perillyl Alcohol in mouse models.
Study on the anti-stress and anti-inflammatory effects of d-Limonene and Perillyl Alcohol.
ETAP-Lab participated in the HIE & NI 2014 event in Amsterdam, showcasing its research and innovations.